公开(公告)号：USD975453S1

公开(公告)日：2023-01-17

申请号：US29720975

申请日：2020-01-16

Applicant: Yan Xu

Designer： Yan Xu

公开(公告)号：USD964049S1

公开(公告)日：2022-09-20

申请号：US29720979

申请日：2020-01-16

Applicant: Yan Xu

Designer： Yan Xu

公开(公告)号：US10323247B2

公开(公告)日：2019-06-18

申请号：US15995134

申请日：2018-06-01

Applicant: Xiaowei Yu ,  Yan Xu

Inventor： Xiaowei Yu ,  Yan Xu

IPC: C12N9/20 ,  C12N15/00 ,  C12N1/20 ,  C12P21/06 ,  C12P21/04 ,  C12N1/14 ,  C07H21/04 ,  C07K1/00 ,  C12N15/62 ,  C07K14/38 ,  C12N15/81 ,  C12N9/50

Abstract: The invention discloses a method for improving the extracellular expression level of a foreign protein by means of phospholipase fusion expression. Four proteins, PLA2, MBP, CBD and SUMO, are used as a fusion tag to construct a fusion gene. Compared with an original protein MOH without any fusion tag, the extracellular expression level and enzymatic activity of all the four fusion proteins are increased to some degree. Among them, the fusion protein using PLA2 as the fusion tag has the highest expression level, which is 7.4 times higher than that of the original protein. Compared with other fusion tags, PLA2 has a low molecular weight and the fusion protein having PLA2 as the fusion tag has the highest expression level (up to 12 g·L−1 in a 7 L fermentation tank for high-density fermentation). It is shown that the secretory expression of a foreign protein can be effectively increased by using PLA2 as a fusion tag.

公开(公告)号：US10091495B2

公开(公告)日：2018-10-02

申请号：US14654804

申请日：2012-12-24

Applicant: Jianping Song ,  Lin Du ,  Yan Xu

Inventor： Jianping Song ,  Lin Du ,  Yan Xu

IPC: H04N21/43 ,  H04N13/30 ,  H04N13/04 ,  H04N5/45 ,  H04N21/431 ,  H04N21/81 ,  H04N13/00

Abstract: One aspect of the disclosed invention relates to a stereoscopic display apparatus comprising: a stereo image acquisition unit configured to acquire a first stereo image for a first image and a second stereo image for a second image; a border generation unit configured to generate a border for separating the first image from the second image; and a displaying unit configured to combine the second stereo image and the generated border with the first stereo image and display the combined stereo images.

公开(公告)号：US10023882B1

公开(公告)日：2018-07-17

申请号：US15641268

申请日：2017-07-04

Applicant: Rongzhen Zhang ,  Yan Xu ,  Yaohui Li

Inventor： Rongzhen Zhang ,  Yan Xu ,  Yaohui Li

IPC: C12N9/02 ,  C12P7/02 ,  C12N11/18 ,  C12P7/22 ,  C12N9/04 ,  C12P17/12

Abstract: Provided are novel hetero-oligomers of (S)-carbonyl reductases and their application in catalyzing the reduction of polyphenyl ketones. Also provided are recombinant strains expressing hetero-oligomers of SCR/SCR2 or SCR2/SCR3, which can catalyze the reduction of polyphenyl ketones. The hetero-oligomer of SCR/SCR2 is capable of catalyzing 2,4-dichlorobenzophenone, 2-naphthalenone and [(E)-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoic acid methyl ester (Keto Easter M) with a specific activity of 4.55 U/mg, 2.43 U/mg and 0.86 U/mg, respectively. The hetero-oligomer of SCR2/SCR3 is capable of catalyzing 2,4-dichlorobenzophenone and [(E)-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoic acid methyl ester (Keto Easter M) with a specific activity of 4.42 U/mg and 1.21 U/mg, respectively. No catalyzing activities for reducing polyphenyl ketones were detected in the naturally existing homo-oligomers of SCR, SCR2 or SCR3, which can catalyze the reduction of monobenzoic cyclic compounds. The invention expands the substrate spectrum of natural (S)-carbonyl reductases (SCR, SCR2 and SCR3) and provides a novel type of oxidoreductases for catalyzing the reduction of polyphenyl ketones.

公开(公告)号：US20170360871A1

公开(公告)日：2017-12-21

申请号：US15633296

申请日：2017-06-26

Applicant: Xun XU ,  Yan XU ,  SHANGHAI FIRST PEOPLE'S HOSPITAL

Inventor： Xun XU ,  Yan XU ,  Qiao SUN

IPC: A61K38/03

CPC classification number: A61K38/03 ,  A61K38/00 ,  C07K14/00 ,  C07K14/4702

Abstract: The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.

公开(公告)号：US09624288B2

公开(公告)日：2017-04-18

申请号：US14650859

申请日：2013-12-09

Applicant: Yan Xu ,  Pei Tang ,  Tommy Tillman

Inventor： Yan Xu ,  Pei Tang ,  Tommy S. Tillman

IPC: C07K14/705 ,  A61K38/00 ,  C07K14/195 ,  C07K14/27 ,  A61K38/16 ,  A61K38/17 ,  B82Y5/00

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K38/164 ,  A61K38/177 ,  B82Y5/00 ,  C07K14/195 ,  C07K14/27 ,  C07K2319/00 ,  C07K2319/03

Abstract: Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed. The use of these compositions and nanoparticles, such as for the treatment of pain, cystic fibrosis and asthma, is also disclosed.

公开(公告)号：US20150266926A1

公开(公告)日：2015-09-24

申请号：US14412497

申请日：2011-12-19

Applicant: Xun Xu ,  Yan Xu

Inventor： Xun Xu ,  Yan Xu

IPC: C07K14/00

CPC classification number: C07K14/001 ,  A61K38/00 ,  C07K14/4705

Abstract: The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.

Abstract translation: 本发明提供富含亮氨酸并用于预防和抑制炎症的多肽及其应用。 本发明还提供了制备多肽的方法和含有多肽的药物组合物。 多肽的优点包括：分子量小，以渗透各种眼组织屏障; 水溶性高，以至于在中性眼泪，房水和玻璃体液中具有高溶解性; 和简单的合成，从而具有较低的制备成本。

公开(公告)号：US08802895B2

公开(公告)日：2014-08-12

申请号：US12906315

申请日：2010-10-18

Applicant: Bin Su ,  Aimin Zhou ,  Yan Xu

Inventor： Bin Su ,  Aimin Zhou ,  Yan Xu

IPC: C07C303/00

CPC classification number: C07C311/08 ,  C07C2601/08 ,  C07D261/18 ,  C07D307/68 ,  C07D317/60 ,  C07D333/38

Abstract: The invention provides a compound of formula (I), a pharmaceutical composition thereof, a method of preparing a medicament for the treatment of a cancer, and a method of treating cancers. The invention exhibits merits against cancers such as significantly higher potency and effectiveness over a broader range of cancers. In formula (I), Ra is a benzyl group with alkyl and/or alkoxy; Rb is selected from H and alkyl groups; Rf is an alkyl; and R3 is selected from a substituted phenyl, a heterocyclic group, and wherein Rc is selected from a fused ring, fused rings, and any bivalent cyclic group.

Abstract translation: 本发明提供式（I）化合物，其药物组合物，制备用于治疗癌症的药物的方法和治疗癌症的方法。 本发明表现出对癌症的优点，例如在更广泛的癌症上显着更高的效力和有效性。 在式（I）中，R a为具有烷基和/或烷氧基的苄基; Rb选自H和烷基; Rf是烷基; 并且R 3选自取代的苯基，杂环基，并且其中R c选自稠环，稠环和任何二价环状基团。

公开(公告)号：US08458420B2

公开(公告)日：2013-06-04

申请号：US12194152

申请日：2008-08-19

Applicant: Lee Charles LaFrese ,  Christopher Michael Sansone ,  Dana Fairbairn Scott ,  Yan Xu ,  Olga Yiparaki

Inventor： Lee Charles LaFrese ,  Christopher Michael Sansone ,  Dana Fairbairn Scott ,  Yan Xu ,  Olga Yiparaki

IPC: G06F12/00

CPC classification number: G06F3/065 ,  G06F3/0617 ,  G06F3/0676 ,  G06F3/0689 ,  G06F12/0238

Abstract: Host input/output (I/O) operations are performed via a file stored in a non-volatile storage coupled to a storage controller while data structures are being generated in the storage controller to copy data from source logical volumes to target logical volumes. The source logical volumes and the target logical volumes are logical representations of physical storage maintained in a plurality of direct access storage devices. The contents of the file are transferred from the non-volatile storage to one or more of the plurality of direct access storage devices, after the data structures have been generated, wherein the host I/O operations are performed via the file while the contents of the file are being transferred to the one or more of the plurality of direct access storage devices. The host I/O operations to the plurality of direct access storage devices are resumed, in response to transferring entire contents of the file to the one or more of the plurality of direct access storage devices.

Abstract translation: 主机输入/输出（I / O）操作通过存储在与存储控制器耦合的非易失性存储器中的文件执行，同时在存储控制器中生成数据结构以将数据从源逻辑卷复制到目标逻辑卷。 源逻辑卷和目标逻辑卷是在多个直接访问存储设备中维护的物理存储器的逻辑表示。 在生成数据结构之后，文件的内容从非易失性存储器传送到多个直接访问存储设备中的一个或多个，其中通过文件执行主机I / O操作， 该文件被传送到多个直接访问存储设备中的一个或多个。 响应于将文件的全部内容传送到多个直接访问存储设备中的一个或多个，恢复对多个直接访问存储设备的主机I / O操作。